# Zepatier in Patients with Substance Use

> **NCT04048850** · — · COMPLETED · sponsor: **University of Illinois at Chicago** · enrollment: 25 (actual)

## Conditions studied

- Hepatitis C
- Hiv
- Coinfection, HIV
- Substance Use Disorders

## Interventions

- **DRUG:** Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]

## Key facts

- **NCT ID:** NCT04048850
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-20
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-09-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04048850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04048850, "Zepatier in Patients with Substance Use". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04048850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*